Key result
Every-other-day pravastatin step-down increases LDL goal failure by ~15 percentage points vs. daily half-dose.
Why the study?
Whether patients who had achieved their NCEP-derived goals for LDL cholesterol with pravastatin would benefit from step-down therapy was uncertain.
Does step-down pravastatin therapy (either every-other-day dosing or halving the daily dose) maintain NCEP-derived LDL cholesterol goals in men who had previously achieved goal on daily pravastatin?
RCT (n=104)
Open-label
Randomized
No
Does step-down pravastatin therapy (either every-other-day dosing or halving the daily dose) maintain NCEP-derived LDL cholesterol goals in men who had previously achieved goal on daily pravastatin?
Step-down pravastatin therapy caused more than half of patients to lose their LDL cholesterol goal, though halving the daily dose resulted in significantly lower end-study LDL levels than every-other-day dosing.
Answers are grounded in this paper and cite their sources.
Step-down pravastatin dosing fails to sustain LDL goals in most patients; challenges routine dose reduction after achievement and supports maintaining full doses.
Study Objective. To determine whether patients who had achieved their National Cholesterol Education Program (NCEP)‐derived goals for low‐density lipoprotein (LDL) cholesterol with pravastatin would benefit from step‐down therapy. Design. Prospective, randomized, open‐label study. Setting. Kansas City Veterans Affairs Medical Center. Patients. One hundred four men who were taking pravastatin once/day and had maintained their NCEP‐defined LDL goal for at least 3 months. Intervention. Fifty‐three patients were randomized to group 1, for which the dosing frequency was changed from daily to every other day, and 51 patients were randomized to group 2, for which the daily dose was halved. Measurements and Main Results. Fasting lipid profiles and hepatic transaminase levels were analyzed at baseline, 2 months, and 4 months. Lifestyle, concomitant drug therapy, adverse events, weight, and compliance were noted at baseline and month 4. Thirty‐one patients (58%) from group 1 and 22 patients (43%) from group 2 did not remain at their LDL goal after step‐down pravastatin therapy. Mean LDL at study end was 113 mg/dl for group 1 and 104 mg/dl for group 2 (p=0.04). Conclusion. More than half (51%) of the patients enrolled did not remain at their LDL goal with step‐down pravastatin therapy. Therefore, we do not recommend a step‐down approach for patients who have achieved their LDL goals. If a clinician decides, however, to attempt dosage reduction, the preferred regimen appears to be to halve the current dose once/day (vs administering the current dose every other day). A fasting lipid profile should be evaluated at 2 months and 4 months after step‐down therapy begins to ensure that desired outcomes are achieved.
No takes yet. Share an insight, caveat, or question.
Graham et al. (2002) conducted an RCT in Hypercholesterolemia / Dyslipidemia at NCEP LDL goal (n=104). Step-down pravastatin every other day vs. Step-down pravastatin with the daily dose halved (once/day) was evaluated on Failure to remain at NCEP-defined LDL goal (and mean LDL at study end) (p=0.04). Step-down pravastatin resulted in 58% of every-other-day vs 43% of half-dose daily patients losing LDL goal, with higher end LDL in the every-other-day group.
Synapse has enriched 10 related papers. Consider them for comparative context: